These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 22354305

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.
    Bordallo-Cardona MÁ, Marcos-Zambrano LJ, Sánchez-Carrillo C, de la Pedrosa EGG, Cantón R, Bouza E, Escribano P, Guinea J.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311063
    [Abstract] [Full Text] [Related]

  • 24. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.
    Locke JB, Almaguer AL, Zuill DE, Bartizal K.
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6100-7. PubMed ID: 27480852
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing.
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
    Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.
    Arendrup MC, Park S, Brown S, Pfaller M, Perlin DS.
    Antimicrob Agents Chemother; 2011 May; 55(5):1891-5. PubMed ID: 21357293
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Analysis of fks1 and fks2 gene mutations in invasive Candida glabrata strains from Pakistan.
    Memon S, Ghanchi NK, Zafar U, Farooqi J, Zaka S, Jabeen K.
    Mycoses; 2023 Jan; 66(1):52-58. PubMed ID: 36106428
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.